Rx for Biotech

What if cancer treatment could find and destroy cancer cells with extraordinary precision while minimizing damage to healthy tissue? In Part 2 of this special Rx for Biotech series, Dr. Babak Saboury and Dr. Eliot Siegel from United Theranostics explain radioligand therapy (RLT), one of the fastest-growing areas in precision medicine and cancer treatment. Radioligand therapies combine advanced ima...

What does it really take to successfully launch a radiopharmaceutical? In Part 1 of this special roundtable “Rx for Biotech” podcast series, Chris Leidli met with Dr. Babak Saboury and Dr. Eliot Siegel, founders of United Theranostics and nationally recognized leaders in nuclear oncology, to discuss one of the biggest challenges facing the radiopharmaceutical industry today: building the infrastru...

What if AI could help women better understand their bodies and take control of their health before problems become crises? In this episode of #RxforBiotech, host Chris Leidli sits down with Kirsten Karchmer, Founder and CEO of Conceivable, to discuss the future of women's health, fertility, hormone health, and personalized medicine. After helping more than 10,000 women improve their fertility and...

What if the future of multiple sclerosis treatment could go beyond suppressing inflammation - and actually help protect the brain? In this episode of Rx for Biotech, host Chris Leidli sits down with Jason Tardio, President & COO of Immunic Therapeutics, to discuss the evolving future of treatment for Multiple Sclerosis (MS), one of the most complex autoimmune and neurodegenerative diseases affecti...

What if your own immune cells could be engineered to fight and even cure cancer? In this episode of Rx for Biotech, host Chris Leidli sits down with Navneet Majhail, MD, a leading expert in blood cancers, bone marrow transplants, and CAR-T cell therapy, to break down one of the most powerful innovations in modern medicine: CAR-T therapy. CAR-T therapy is a form of immunotherapy that uses a patient...

Why is brain cancer so hard to detect and treat - and what if we could change that? In this episode of Rx for Biotech, host Chris Leidli sits down with Marc Hedrick, CEO of Plus Therapeutics, and Russell Bradley, General Manager of CNSide Diagnostics, to explore a new, integrated approach to treating some of the most challenging cancers in medicine: central nervous system (CNS) cancers, including...

What if you could get a Transplant and Reset your Immune System in less than 48 Hours? In this episode of Rx for Biotech, host Chris Leidli sits down with Kevin Caldwell, CEO of Ossium Health, to explore how bone marrow transplants, cell therapy, and bioengineered immune systems are transforming the future of medicine. Ossium Health is building a first-of-its-kind bone marrow banking platform, usi...

What if chemotherapy could target tumors without harming the rest of the body? In this episode of *Rx for Biotech*, host Chris Leidli sits down with Christina Coughlin, MD, PhD, CEO of Avacta Therapeutics, to explore a new approach to cancer treatment using targeted chemotherapy and precision oncology. Avacta is developing a novel platform designed to activate powerful cancer drugs only inside the...

What if a simple blood test could reveal how your body responds to disease - or even help doctors choose the right treatment for you? In this episode of Rx for Biotech, host Chris Leidli speaks with Mo Jain, MD, PhD, co-founder of Sapient, about how scientists are using advanced biology and artificial intelligence to uncover new biomarkers - the biological signals that can help doctors understand...

In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan). We discuss: * How PSMA-targeted radioligand therapy delive...

What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer’s? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful...

A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.

This episode is about hope, and about a different way of thinking about cancer treatment. My guest is Dr. Øystein Rekdal, CEO and co-founder of Lytix Biopharma. Øystein is a scientist and leader who has spent decades studying how the immune system works - and how it can be helped to recognize and fight cancer more effectively. Rather than focusing only on destroying tumors, Lytix is working on the...

InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.

In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localiz...

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic tripl...

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision dia...

Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies. In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and w...

In this podcast episode, Dr. Kilian Kelly, CEO of Cynata Therapeutics, discusses the future of regenerative medicine! Discover how mesenchymal stem cells (MSCs)—powerful cells that repair and regenerate tissues—are revolutionizing treatments for a range of diseases. Dr. Kelly shares insights on Cynata’s groundbreaking Cymerus™ platform and the exciting potential of MSC therapies.

Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.

AI is transforming job search, recruiting and hiring practices. Our guest in this podcast episode is Steve Swan, Practice Leader at The Swan Group. Steve is an Executive Recruiter specializing in technology for the Pharmaceutical and Biotech Industry. In this episode Steve shares his insights on how AI is transforming the hiring process.

Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his...